Navigation Links
Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
Date:2/11/2010

MOUNTAIN VIEW, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food & Drug Administration has accepted the AZ-004 NDA for filing and has indicated a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  Alexza filed the AZ-004 NDA on December 11, 2009 and is seeking marketing approval for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials.  In February 2010, Alexza established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation ( BVF), to develop and commercialize AZ-004 in the U.S. and Canada.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004.  Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  Alexza's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in Alexza's Annual Report on Form 10-K for the year ended December 31, 2008, and Alexza's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the heading: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials." Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

RELATED LINKS
http://www.alexza.com

'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
2. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
3. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
4. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
5. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
6. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
7. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
8. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
9. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
(Date:5/23/2016)... , May 23, 2016 The World Health Organization ... device to include adolescents aged 13 years, and above. ... be offered for adult and adolescent males in the 14 ... . PrePex was the first male circumcision device to receive ... CEO, Eddy Horowitz said: " The expanded ...
(Date:5/23/2016)... -- Experts from various countries ... role of technology in innovative healthcare ... International Conference of VPS-Penn Medicine opened in Abu ... Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Culture and ... provide personalized medicine and tailor-made healthcare in disease treatment and ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of ... will ever be totally eliminated, many human performance problems can be prevented. , How ...
(Date:5/24/2016)... ... 2016 , ... Regenerative Medicine is being transformed by ongoing research and clinical ... and patient results as have been achieved with Okyanos Cell Therapy are ... care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric Duckers, ...
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... ... treatment for physical disease or injury that focuses on repairing the musculoskeletal and ... , With an emphasis on functional restoration, NYDNRehab began providing treatments for physical ...
(Date:5/24/2016)... ... , ... A newly released report reveals that improving life outcomes for boys ... in face-to-face interactions and online. In “Heard, Not Judged – Insights into the Talents, ... of mobile digital devices can be an effective tool to help boys and men ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... ... to advancing the science and clinical practice of radiosurgery, is recognizing five medical ... stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will be presented ...
Breaking Medicine News(10 mins):